Concepedia

Andreas Mantoulidis

AM

6

Publications

1K

Citations

6

H-Index

2019

Active since

Affiliations

Boehringer Ingelheim (Austria)(Current)

Vanderbilt University

Andreas Mantoulidis is an author at Boehringer Ingelheim (Austria) specializing in tumor biology, medicinal chemistry, and drug discovery.

Top concepts

Publications per year

2019–2024

6

Publications

6

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

Dong-Sung Kim, Lorenz Herdeis, Dorothea Rudolph et al. · Nature · 2023 · 448 citations · Full text

Drugging an undruggable pocket on KRAS

Dirk Kessler, Michael Gmachl, Andreas Mantoulidis et al. · Proceedings of the National Academy of Sciences · 2019 · 415 citations · Full text

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS <sup>G12C</sup> Inhibitor

Joachim Bröker, Alex G. Waterson, Chris A. Smethurst et al. · Journal of Medicinal Chemistry · 2022 · 72 citations · Full text

Homo-BacPROTAC-induced degradation of ClpC1 as a strategy against drug-resistant mycobacteria

Lukas Junk, Volker M. Schmiedel, Somraj Guha et al. · Nature Communications · 2024 · 37 citations · Full text

Abstract 1271: <i>In vitro</i> and <i>in vivo</i> characterization of BI 1823911 - a novel KRASG12C selective small molecule inhibitor

Fabio Savarese, Andreas Gollner, Dorothea Rudolph et al. · Cancer Research · 2021 · 22 citations

, , +23

Rows per page

1–5 of 6